Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

GH Research PLC

GHRS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$28.92

▲ +2.92%

Market Cap $1.99B · Vol 35.81K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.99B

Small Cap

Div Yield

N/A

EPS Growth

-53.02%

YoY

RSI (14)

49.04

Momentum

Beta

1.29

vs Market

52W High

$31.17

7.20% below

52W Low

$11.85

144.05% above

Volume

35.81K

Avg 74.56K

P/B

2.82

Price-to-book

ROE

-21.04%

Return on equity

Free Float

74.43%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, GH Research PLC (GHRS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GHRS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.74%

+6.01%

+30.74%

+83.62%

YTD

+127.72%

+119.42%

+188.05%

+36.16%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-48,258,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-21.04%
ROA · ROIC	-20.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.82
P/FCF	N/A
EPS Growth	-53.02%
Outstanding Shares	68.64M

Technical Indicators

50-Day SMA	$27.29
200-Day SMA	$19.27
RSI (14)	49.04
Beta	1.29
52-Week High	$31.17
52-Week Low	$11.85

Volume Today	35.81K
Avg Daily Volume (30D)	74.56K
Relative Volume	0.48x
Volatility (10D)	53.25
Volatility (30D)	47.35
Free Float	74.43%

Analyst Consensus

BUY

Current Price $28.92

Mean Target $41.70

52W Low$11.85 52W High$31.17

Current

Target

$11.85 $31.17

Current Analyst target

+44.19% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011BQC422

ISINIE000GID8VI0

CountryIreland

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.